Does a valuation cap set the company's actual valuation?

No, a valuation cap is not a valuation of the company, it is only a ceiling on the price used to convert a specific convertible instrument into equity, and it is often set well below what the company or investors believe the eventual priced round valuation will be. Treating the cap as a public statement of company value is a common founder mistake that can create confusion with employees, later investors, or acquirers who see the cap referenced in cap table software. The actual valuation is determined later, when a priced equity round sets a real pre-money valuation through negotiation.

What is the relationship between a valuation cap and pre-money valuation at conversion?

At conversion, the cap effectively functions as a pre-money valuation ceiling: the noteholder's conversion price is calculated as if the company were valued at the cap, regardless of what pre-money valuation is negotiated for the new investors in that round. This is why a company that raises its priced round well above the cap will see early investors convert at a much lower effective price per share than the new round's investors, creating meaningfully different ownership outcomes for capital that came in at different times. Founders need to model this gap explicitly, since it directly affects dilution to common stockholders.

What mistake do founders make when negotiating valuation caps across multiple bridge rounds?

A common mistake is agreeing to progressively lower caps under time pressure without modeling the combined dilutive effect once all instruments convert together at the priced round, since each successive cap compounds the ownership given to earlier investors. Another frequent error is failing to communicate the cap's implications to the board or to later investors, who may be surprised by the effective ownership early bridge investors receive once the full stack converts. Running a full conversion model under multiple future valuation scenarios before signing each new instrument helps avoid both problems.

Back to Founder & Investor Primer

Investment & FinanceStartup Lifecycle

Valuation Cap

Maximum company valuation at which a SAFE or note converts to equity.

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

Definition

A valuation cap sets a ceiling on the price at which a convertible instrument converts into equity, protecting early investors from dilution if the company's valuation rises sharply before the next priced round. At conversion, the investor gets the better of the cap price or the discounted round price, not both. A post-money cap fixes the investor's ownership percentage, while a pre-money cap can shift with other converting instruments. Setting a cap too low can create heavy dilution and signal a low valuation to later investors.

What the regulation says

A valuation cap is a negotiated conversion term, not a valuation limit prescribed by MedTech regulation. FDA and EMA requirements do not determine its amount or conversion mechanics. In the United States, the Securities Act of 1933, enacted May 27, 1933, governs securities offerings: Section 5 generally requires registration unless an exemption applies, while Section 4(a)(2) exempts transactions by an issuer not involving a public offering. A SAFE or convertible note offering therefore needs an appropriate securities-law basis, regardless of the agreed cap. Regulation D provides commonly used exemptions. Rule 506(b), 17 CFR 230.506(b), prohibits general solicitation; Rule 506(c), effective September 23, 2013, permits it if all purchasers are accredited investors and the issuer takes reasonable steps to verify that status. Exempt offerings remain subject to antifraud requirements, including Securities Act Section 17(a). Statements about the cap, discount, capitalization assumptions and dilution must not be materially misleading. Documents should explain which conversion price applies and how other instruments affect ownership. A post-money cap should not be described as guaranteeing a permanent ownership percentage: subsequent financing can dilute it. These are contractual and securities-law issues, separate from device authorization.

What this means in practice

In MedTech, caps are calibrated to expected milestones - caps often step up after first-in-human data, CE mark, or FDA clearance. A cap that's too low gives away too much equity; too high and early investors won't bite.

Examples

A startup raises a seed round with a SAFE that includes a $10 million valuation cap. If the Series A round values the company at $20 million, the SAFE investors convert their investment at the $10 million cap, receiving more shares than if they converted at the $20 million round price.
A MedTech company developing a novel diagnostic device secures early funding with a convertible note that has a $15 million valuation cap, anticipating a significant valuation increase after completing its first-in-human study and securing initial regulatory clearance.
Investors decide to pass on a promising MedTech startup's convertible note offer because the proposed $50 million valuation cap is deemed too high for the current stage of development, limiting their potential upside and indicating significant future dilution if the company doesn't meet very ambitious milestones.

Common pitfalls

•Negotiating a cap without modeling the implied ownership percentage at conversion under various Series A scenarios.

Frequently asked questions

Because a valuation cap effectively fixes the price at which the note or SAFE converts to equity, it should be calibrated to the company's expected valuation trajectory, with lower caps for capital raised well before de-risking events like first-in-human data or 510(k) clearance and higher caps for capital raised closer to or after those events. Setting the cap too low relative to a milestone that has already been achieved gives away more equity than necessary, while setting it unrealistically high can make the round unattractive to investors who won't see meaningful upside if the next round prices near the cap. Many MedTech bridge structures use step-up caps tied explicitly to milestone achievement to address this tension directly.

Grouped by theme

Editor's picks

· Hand-selected related concepts

Investment & Finance

Convertible Note

Short-term debt that converts into equity at a future financing round.

Investment & Finance

Pre-Money Valuation

Company valuation immediately before new money is invested.

Investment & Finance

Simple Agreement for Future Equity(SAFE)

Convertible instrument that converts to equity at a future priced round.

Founder & Investor Primer

· From this learning path

Investment & Finance

Capitalization Table(Cap Table)

Ledger of all securities issued by a company and who owns them.

Adjacent lesson

Investment & Finance

Term Sheet

Non-binding outline of the key economic and control terms of an investment.

Adjacent lesson

Investment & Finance

Due Diligence

Investigation of a company before an investment, financing, or acquisition.

Investment & Finance

Exit Multiple

Valuation ratio applied at exit, e.g., enterprise value to revenue.

Latest in MedTech

Sources

3 sources

Every citation below opens the original document. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

Tier 4Trade press and expert commentary· 3

Link health: 3 verified· last checked 2026-06-20

Carta·1PitchBook·1NVCA·1

Inline markers like [1] jump to the matching reference above.

My progress

All terms0 / 513

Investment & Finance0 / 47

Saved on this device, and to your account when signed in. View studied terms

Full glossary

Browse all terms A to Z, each with a short definition.

On this term

Category: Investment & Finance
Sources: 3
Updated: 5/5/2026

Compare with another term

Learn in 60 seconds

Maximum company valuation at which a SAFE or note converts to equity.

·In MedTech, caps are calibrated to expected milestones - caps often step up after first-in-human data, CE mark, or FDA clearance.
·A cap that's too low gives away too much equity; too high and early investors won't bite.
·At conversion, the investor gets the better of the cap price or the discounted round price, not both.

Remember this

Watch out: Negotiating a cap without modeling the implied ownership percentage at conversion under various Series A scenarios.

Related terms

You may also need

Auto-suggested from Investment & Finance and shared keywords.

All Investment & Finance terms

Definition

What this means in practice

Examples

Frequently asked questions

Related terms

Editor's picks

Founder & Investor Primer

More in Investment & Finance

Latest in MedTech

Sources